FDA approves first treatment for a condition associated with early-onset pediatric cataracts
The US Food and Drug Administration (FDA) approved Ctexli™ (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. This is the first FDA-approved treatment for CTX, which is a rare lipid storage disease that can be associated with pediatric bilateral cataracts.
The approval was based on results from a 24-week, double-blind, placebo-controlled, randomized, crossover study that assessed chenodiol 250 mg administered three times per day. Compared with placebo, chenodiol significantly reduced plasma cholestanol and urine 23S-pentol.
The most common adverse events associated with chenoidiol are diarrhea, headache, abdominal pain, constipation, hypertension, muscular weakness, and upper respiratory tract infection.
See the press release for full information.
Related Content
